The latest price target for Adaptive Biotechnologies (NASDAQ:ADPT) was reported by Piper Sandler on August 4, 2026. The analyst firm set a price target for $27.50 expecting ADPT to rise to within 12 months (a possible 13.41% upside). 23 analyst firms have reported ratings in the last year.

The latest analyst rating for Adaptive Biotechnologies (NASDAQ:ADPT) was provided by Piper Sandler, and Adaptive Biotechnologies maintained their overweight rating.

The last upgrade for Adaptive Biotechnologies Corp happened on March 21, 2025 when Goldman Sachs raised their price target to $9. Goldman Sachs previously had a neutral for Adaptive Biotechnologies Corp.

There is no last downgrade for Adaptive Biotechnologies.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adaptive Biotechnologies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adaptive Biotechnologies was filed on August 4, 2026 so you should expect the next rating to be made available sometime around August 4, 2027.

While ratings are subjective and will change, the latest Adaptive Biotechnologies (ADPT) rating was a maintained with a price target of $20.00 to $27.50. The current price Adaptive Biotechnologies (ADPT) is trading at is $24.25, which is within the analyst’s predicted range.